Brand-Name, Generics Deals Stifle Competition: FTC

Law360, New York (May 21, 2008, 12:00 AM EDT) -- Patent settlements in which drugmakers pay their generics rivals to keep generic competition off the market may stifle competition, according to a report from the U.S. Federal Trade Commission released on Tuesday.

"This report confirms that settlements with potentially anti-competitive arrangements continue to be prevalent," said FTC Chairman William E. Kovacic. "The commission remains committed to ensuring that brand and generic companies do not use such settlements as a way to deny consumers the benefits of competition."

There were 33 final settlements in pharmaceutical patent cases...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.